These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 8505410

  • 1. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.
    Wang ZY, Qiao J, Link H.
    J Neuroimmunol; 1993 May; 44(2):209-14. PubMed ID: 8505410
    [Abstract] [Full Text] [Related]

  • 2. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
    Wang ZY, Huang J, Olsson T, He B, Link H.
    J Neurol Sci; 1995 Feb; 128(2):167-74. PubMed ID: 7537794
    [Abstract] [Full Text] [Related]

  • 3. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor.
    Ma CG, Zhang GX, Xiao BG, Link J, Olsson T, Link H.
    J Neuroimmunol; 1995 Apr; 58(1):51-60. PubMed ID: 7537280
    [Abstract] [Full Text] [Related]

  • 4. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
    Wang ZY, Qiao J, Melms A, Link H.
    Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
    [Abstract] [Full Text] [Related]

  • 5. Suppression of experimental autoimmune myasthenia gravis and experimental allergic encephalomyelitis by oral administration of acetylcholine receptor and myelin basic protein: double tolerance.
    Wang ZY, He B, Qiao J, Link H.
    J Neuroimmunol; 1995 Dec; 63(1):79-86. PubMed ID: 8557828
    [Abstract] [Full Text] [Related]

  • 6. B cell autoimmunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis.
    Wang ZY, Link H, Qiao J, Olsson T, Huang WX.
    J Neuroimmunol; 1993 Jun; 45(1-2):103-12. PubMed ID: 8331155
    [Abstract] [Full Text] [Related]

  • 7. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals.
    Shi FD, Bai XF, Li HL, Huang YM, Van der Meide PH, Link H.
    Clin Exp Immunol; 1998 Mar; 111(3):506-12. PubMed ID: 9528890
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nasal tolerance to experimental autoimmune myasthenia gravis: tolerance reversal by nasal administration of minute amounts of interferon-gamma.
    Li HL, Shi FD, Bai XF, Huang YM, van der Meide PH, Xiao BG, Link H.
    Clin Immunol Immunopathol; 1998 Apr; 87(1):15-22. PubMed ID: 9576006
    [Abstract] [Full Text] [Related]

  • 14. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
    Okumura S, McIntosh K, Drachman DB.
    Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
    [Abstract] [Full Text] [Related]

  • 15. Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of experimental autoimmune myasthenia gravis with a peptide vaccine.
    Araga S, Blalock JE.
    Immunomethods; 1994 Oct; 5(2):130-5. PubMed ID: 7874437
    [Abstract] [Full Text] [Related]

  • 16. 'Split tolerance' induction by intrathymic injection of acetylcholine receptor in a rat model of autoimmune myasthenia gravis; implications for the design of specific immunotherapies.
    Ohtsuru I, Matsuo H, Fukudome T, Suenaga A, Tsujihata M, Nagataki S.
    Clin Exp Immunol; 1995 Dec; 102(3):462-7. PubMed ID: 8536358
    [Abstract] [Full Text] [Related]

  • 17. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
    Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JB.
    J Immunol; 1996 Jul 01; 157(1):386-92. PubMed ID: 8683141
    [Abstract] [Full Text] [Related]

  • 18. Prevention of experimental autoimmune myasthenia gravis in rats by fetal alpha-fetoprotein-rich fractions.
    Brenner T, Zielinski A, Argov Z, Abramsky O.
    Tumour Biol; 1984 Jul 01; 5(5):263-74. PubMed ID: 6085187
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.
    Wauben MH, Hoedemaekers AC, Graus YM, Wagenaar JP, van Eden W, de Baets MH.
    Eur J Immunol; 1996 Dec 01; 26(12):2866-75. PubMed ID: 8977279
    [Abstract] [Full Text] [Related]

  • 20. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.
    Balasa B, Deng C, Lee J, Bradley LM, Dalton DK, Christadoss P, Sarvetnick N.
    J Exp Med; 1997 Aug 04; 186(3):385-91. PubMed ID: 9236190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.